F 573

Drug Profile

F 573

Alternative Names: CV 1013; EP 1013; F573; MX 1013

Latest Information Update: 30 Aug 2013

Price : $50

At a glance

  • Originator EpiCept Corporation
  • Developer EpiCept Corporation; GNI
  • Class Antineoplastics; Dipeptides; Small molecules
  • Mechanism of Action Caspase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Viral hepatitis
  • No development reported Transplant rejection
  • Discontinued Liver disorders; Multiple organ failure; Myocardial infarction; Septic shock; Stroke

Most Recent Events

  • 20 Aug 2013 EpiCept Corporation has been acquired by Immune Pharmaceuticals Ltd
  • 04 Apr 2012 Final pharmacodynamics data from a preclinical trial in Liver damage released by Epicept
  • 08 Apr 2010 No development reported - Preclinical for Transplant rejection in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top